Your ultimate guide to the closed-off world of biotech venture capital

Now in its sixth year, the STAT Report, Ranking Biotech’s Top Venture Capital Firms, has become the go-to guide for understanding who’s truly delivering in the high-stakes world of biotech investing. Based on the latest performance data, this year’s edition offers our most comprehensive, data-driven analysis yet, including firm rankings, strategic insights, and new names making waves in the biotech VC space.

From industry giants to emerging powerhouses, STAT News’ Allison DeAngelis unpacks the stories behind the numbers.

Inside the 2025 STAT Report, you’ll get:

• Rankings of top biotech VC firms based on private return data
• Analysis of firm strategies, successes, and trends
• Fresh data revealing how investors performed in a volatile market
• Shifts among legacy players and newcomers to watch

Why This Report Matters

The biotech venture capital space is evolving fast, and so are the firms driving it. STAT's unique methodology offers a sweeping examination of biotech VC operations, unlike any other. Whether you’re an investor, a startup founder looking for the right backers, or simply someone watching where some of biotech’s money is going, this report gives you a clear view of who’s delivering the best returns and why.

Buy the 2024 Edition and 2025 Edition together and save big! Enjoy an 80% discount on the 2024 edition automatically applied at checkout.

For information on licensing this report for external distribution or marketing, please visit our partners at PARS here. Please also refer to the Terms and Conditions for additional information on use.